Abbott Laboratories Reports $44.3 Billion in Net Sales for Fiscal Year 2025

Abbott Laboratories reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with total net sales reaching $44.3 billion, a 5.7% increase from $42.0 billion in 2024. The company's operating earnings also rose to $8.1 billion, compared to $6.8 billion in the previous year, reflecting an operating margin improvement from 16.3% to 18.2%. However, net earnings decreased to $6.5 billion from $13.4 billion in 2024, primarily due to a one-time tax benefit recognized in the prior year.

Abbott's growth was driven by strong performances in its Medical Devices and Established Pharmaceutical Products segments, which saw sales increases of 12.6% and 6.6%, respectively. The Medical Devices segment, particularly, benefited from robust demand for continuous glucose monitoring systems, which generated $7.6 billion in sales. In contrast, the Diagnostics segment experienced a decline of 4.5% in sales, largely attributed to reduced demand for COVID-19 testing products, which fell to $297 million from $747 million in 2024.

Strategically, Abbott announced its intention to acquire Exact Sciences Corporation for approximately $21 billion, a move aimed at expanding its footprint in the cancer diagnostics market. This acquisition is expected to be financed through a combination of cash and a $20 billion bridge loan facility. Additionally, Abbott completed the acquisition of Cardiovascular Systems, Inc. in April 2023, further enhancing its medical device portfolio.

Operationally, Abbott employed approximately 115,000 individuals as of December 31, 2025, with 69% of its workforce based outside the United States. The company reported a 5.1% increase in sales from emerging markets, which accounted for 37% of total sales. Despite challenges in the U.S. market, particularly in the Nutritional Products segment, where sales remained flat due to lower volumes, Abbott's international sales growth and strategic acquisitions position the company for continued expansion.

Looking ahead, Abbott plans to focus on driving growth through product development and market expansion across its segments. The company aims to leverage its recent acquisitions and enhance its product offerings to meet evolving consumer needs, particularly in the diagnostics and medical devices sectors. Abbott's management remains optimistic about future performance, despite the challenges posed by regulatory environments and market conditions.